Reviva Pharmaceuticals (RVPH) Projected to Release Earnings on Thursday

Reviva Pharmaceuticals (NASDAQ:RVPH) is expected to be issuing its Q2 2026 resultson Thursday, August 13th. Analysts expect Reviva Pharmaceuticals to post earnings of ($0.36) per share for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 17, 2026 at 4:00 PM ET.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). On average, analysts expect Reviva Pharmaceuticals to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Reviva Pharmaceuticals Stock Up 0.3%

Shares of RVPH stock opened at $0.43 on Tuesday. Reviva Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $17.20. The company has a market capitalization of $5.64 million, a PE ratio of -0.11 and a beta of 0.53. The firm has a 50 day moving average price of $0.58 and a two-hundred day moving average price of $1.89.

Wall Street Analyst Weigh In

A number of research firms have commented on RVPH. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen raised Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, July 5th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Reviva Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $66.67.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of institutional investors have recently modified their holdings of RVPH. XTX Topco Ltd purchased a new stake in shares of Reviva Pharmaceuticals in the second quarter worth approximately $31,000. Lido Advisors LLC bought a new stake in Reviva Pharmaceuticals during the third quarter worth $37,000. NewEdge Advisors LLC bought a new stake in Reviva Pharmaceuticals during the first quarter worth $58,000. State Street Corp raised its position in Reviva Pharmaceuticals by 202.4% in the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after buying an additional 256,500 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after buying an additional 29,063 shares during the last quarter. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.